12:00 AM EDT, 09/22/2026 (MT Newswires) -- The European Commission approved obicetrapib as a treatment for primary hypercholesterolemia, marking the first regulatory approval for the drug worldwide. NewAmsterdam Pharma Co and Menarini Group said Monday that the regulator issued the marketing authorization for 10-milligram monotherapy Ubeslo and the combination formulation Evlarco for both heterozygous familial hypercholesterolemia and non-familial or mixed dyslipidemia. The application for obicetrapib was supported with data from a clinical development program, including results from the phase 3 Broadway, Brooklyn and Tandem trials. A positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use also preceded the approval. NewAmsterdam and Menarini are also developing obicetrapib for cardiovascular applications.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.